hackint0sh/New-Dataset huggingface dataset:
In total 140 preterm infants, including 70 BPD patients and 70 preterm controls, born below 30 weeks' gestation at the Antwerp University Hospital will be included. conditions: Bronchopulmonary Dysplasia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 140 type: ESTIMATED name: Breath test name: Throat swabs name: Placental samples name: Vaginal swab name: Endotracheal aspirates measure: Exhaled breath Volatile Organic Compounds (VOCs) measure: Airway mucin profiles measure: Airway microbial profiles measure: Placental headspace VOCs measure: Placental microbiome measure: Vaginal microbiome measure: Follow-up structural lung imaging measure: Hypercapnia sex: ALL minimumAge: 0 Days maximumAge: 3 Days stdAges: CHILD hasResults: False
nctId: NCT06342739 id: IEO 1595 briefTitle: Verbal Synchrony, Satisfaction and Decision-making in Face-to-face Consultations overallStatus: RECRUITING date: 2022-03-23 date: 2024-12-31 date: 2024-12-31 date: 2024-04-02 date: 2024-04-02 name: European Institute of Oncology class: OTHER briefSummary: Eligible participants will be: benign thyroid nodules patients, to be involved in a consultation with their endocrinologist and/or surgeon and/or radiologist, in order to discuss treatment options related to benign thyroid nodules. conditions: Thyroid Nodule studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 60 type: ESTIMATED measure: Evaluation of predictive power of verbal synchrony established between patient and physician during the consultation on patients' satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan country: Italy name: Gabriella Pravettoni role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06342726 id: 2024/714469 briefTitle: The Effect of Active External Rewarming on Rewarming Rate in Simulated Prehospital Accidental Hypothermia overallStatus: RECRUITING date: 2024-05-28 date: 2024-06-02 date: 2024-06-02 date: 2024-04-02 date: 2024-04-02 name: Haukeland University Hospital class: OTHER briefSummary: In this study, we aim to compare the effect of active external rewarming to passive rewarming in healthy research participants on core temperature.
The participants will be cooled to a core temperature of 35 degress C, the rewarmed using 2 different scenarios. Scenario 1 will be with passive rewarming, scenario 2 with active rewarming. Shivering will be pharmacologically inhibited using Buspirone and Meperidine. conditions: Accidental Hypothermia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The study will use a crossover design on where research participants will undergo repetitions of the same scenario with different interventions in order to serve as their own control. The research participants will be healthy volunteers providing both oral and written consent.
When the research subjects reach the target temperature of 35.0°C or the maximum cooling time of 2 hours, they will be subjected to one of the two scenarios listed below, with a rewarming phase of maximum 60 minutes. primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 12 type: ESTIMATED name: PAX Warming Blanket name: Passive insulation measure: Core body temperature sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Haukeland University Hospital status: RECRUITING city: Bergen zip: 5021 country: Norway name: Sigurd Mydske, MD role: CONTACT phone: 90659586 email: sigurd.mydske@norskluftambulanse.no name: Øyvind Thomassen, MD, PhD role: CONTACT phone: 977 18 721 email: oyvind.thomassen1@helse-bergen.no lat: 60.39299 lon: 5.32415 hasResults: False
nctId: NCT06342713 id: BGB-45035-101 briefTitle: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 overallStatus: NOT_YET_RECRUITING date: 2024-05-28 date: 2025-04-30 date: 2025-04-30 date: 2024-04-02 date: 2024-04-02 name: BeiGene class: INDUSTRY briefSummary: This study is the first-in-human (FIH) study for BGB-45035. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGB-45035 with both a single dose and multiple doses administered at different dose levels in healthy participants.
* Safety follow-up 30 days after last dose of study drug. conditions: Healthy Participants conditions: Healthy Subjects conditions: Healthy Volunteers conditions: Autoimmune Diseases conditions: Healthy Adult Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The cohorts in Part A, B, and C will be double-blinded, while the food effect study in Part D will be open-label whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 92 type: ESTIMATED name: BGB-45035 name: Placebo measure: Number of Participants Experiencing Adverse Events (AEs) measure: Number of participants with clinically significant changes from baseline in clinical laboratory values measure: Number of participants with clinically significant changes from baseline in vital signs measure: Number of participants with clinically significant changes from baseline in cardiac conduction intervals measure: Area under the plasma concentration time curve from time zero to last quantifiable time(AUClast) measure: Area under the plasma concentration time curve from time zero to infinite time (AUCinf) measure: Area under the plasma concentration time curve from time zero to end of dosing interval (AUCtau) measure: Maximum observed plasma concentration (Cmax) measure: Time to maximum plasma concentration (Tmax) measure: Trough plasma concentration (Ctrough) measure: Half life (t½) measure: Apparent systemic clearance (CL/F) measure: Apparent volume of distribution (Vz/F) measure: Accumulation Ratios sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06342700 id: PKM18138 id: U1111-1299-1906 type: REGISTRY domain: ICTRP briefTitle: A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants overallStatus: RECRUITING date: 2024-03-25 date: 2024-04-29 date: 2024-04-29 date: 2024-04-02 date: 2024-04-11 name: Sanofi class: INDUSTRY briefSummary: This is a cross-over, Phase 1, 4-arm study. The purpose of this study is to measure the relative bioavailability and food effect of crystalline formulation rilzabrutinib and amorphous formulation rilzabrutinib in healthy male and female participants aged 18 to 55 years of age.
* Safety follow-up: participants will be asked to participate in an end-of-study safety assessment upon discharge from the clinical study unit, ie, on Day 8 of the study. conditions: Autoimmune Disorder conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: NONE count: 28 type: ESTIMATED name: Rilzabrutinib crystalline form name: Rilzabrutinib amorphous form measure: Relative bioavailability as assessed by rilzabrutinib Cmax following administration of the test and reference formulations in the fasted state measure: Relative bioavailability as assessed by rilzabrutinib AUClast following administration of the test and reference formulations in the fasted state measure: Relative bioavailability as assessed by rilzabrutinib AUC following administration of the test and reference formulations in the fasted state measure: Relative bioavailability as assessed by rilzabrutinib Cmax following administration of the test and reference formulations in the fed state measure: Relative bioavailability as assessed by rilzabrutinib AUClast following administration of the test and reference formulations in the fed state measure: Relative bioavailability as assessed by rilzabrutinib AUC following administration of the test and reference formulations in the fed state measure: Food effects as assessed by rilzabrutinib Cmax following administration of the test and reference formulations under the fed versus fasted state measure: Food effects as assessed by rilzabrutinib AUClast following administration of the test and reference formulations under the fed versus fasted state measure: Food effects as assessed by rilzabrutinib AUC following administration of the test and reference formulations under the fed versus fasted state measure: Number of participants with adverse events, treatment-emergent adverse events, serious adverse events and adverse events of special interest sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Nucleus Network Site Number : 8400001 status: RECRUITING city: Saint Paul state: Minnesota zip: 55114 country: United States lat: 44.94441 lon: -93.09327 hasResults: False
nctId: NCT06342687 id: JagiellonianU 1 briefTitle: Compliance With ERAS and Five Year Survival After Colorectal Cancer Treatment overallStatus: COMPLETED date: 2018-01-01 date: 2022-12-31 date: 2023-12-31 date: 2024-04-02 date: 2024-04-02 name: Jagiellonian University class: OTHER briefSummary: The Enhanced Recovery after Surgery (ERAS) protocol has transformed perioperative care, representing a significant paradigm shift in managing colorectal cancer patients. While the immediate benefits of Enhanced Recovery After Surgery (ERAS) in expediting postoperative recovery are well-documented and widely acknowledged, it is essential to investigate its long-term implications, particularly its influence on survival rates. The aim of this study will be to analyse the impact of compliance with the ERAS protocol on long- term outcomes after laparoscopic colorectal resection. conditions: Colorectal Cancer conditions: ERAS studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 468 type: ACTUAL name: High compliance with ERAS protocol measure: Post operative 5 year survival rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jagiellonian University Medical College city: Kraków state: Małopolskie zip: 31-008 country: Poland lat: 50.06143 lon: 19.93658 hasResults: False
nctId: NCT06342674 id: Nejla CANBULAT ŞAHİNER briefTitle: Effect of Breast Milk Circadian Properties on Infant's Growth Parameters and Absorption of Nutrients acronym: The overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-04-01 date: 2025-07-31 date: 2024-04-02 date: 2024-04-02 name: Sakarya University class: OTHER briefSummary: The most ideal method for providing breast milk is breastfeeding. However, it may be necessary to express breast milk for reasons such as the newborn being in an intensive care unit, the mother being hospitalized for any reason, or the mother starting to work. The content of breast milk varies according to gestational age and stages of lactation. However, it varies from day to day depending on the infant's needs. In recent literature, it is emphasized that the content of breast milk (carbohydrates, fats, proteins, vitamins, trace elements, etc.) varies according to circadian variation. In the literature review, no national or international study was found indicating whether the circadian properties of breast milk have an effect on the infant's growth parameters. This study was designed as a randomized controlled experimental study to determine the effect of the circadian properties of breast milk on the growth parameters of the infant and the absorption levels of nutrients by the baby in preterm newborns.
Hypothesis 4 (H4): Feeding preterm newborns with breast milk according to the circadian rhythm has an effect on the absorption levels of vitamins and trace elements measured in the infants' breast milk. conditions: Breast Feeding conditions: Breast Milk Collection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Controlled Trial primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Single (participant) blinding was used in the study. For this purpose, it was not stated which group the participating mothers were in the research, but they were informed about the procedure to be performed. Therefore, a separate informed consent form was prepared for each group. Statistician blinding will also be applied. While coding the research data, the research group will be coded as A and B, and the statistician will be prevented from knowing which letter represents which group. whoMasked: OUTCOMES_ASSESSOR count: 44 type: ESTIMATED name: Giving breast milk to the newborn according to the circadian rhythm name: Usual care measure: Evaluation of the newborn's body weight in the study and control groups Evaluation of the newborn's body weight in the study and control groups Evaluation of the newborn's body weight in the study and control groups measure: Evaluation of the baby's height measurements in the study and control groups measure: Evaluation of the baby's head circumference in the study and control groups measure: Evaluation of nutritional absorption of infants in the study and control groups sex: ALL minimumAge: 32 Weeks maximumAge: 34 Weeks stdAges: CHILD hasResults: False
nctId: NCT06342661 id: 2022IIT205 briefTitle: Study On the Expression Level and Clinical Significance of VISTA in Patients With Vascular Cognitive Impairment overallStatus: RECRUITING date: 2023-03-01 date: 2028-11 date: 2028-11 date: 2024-04-02 date: 2024-04-02 name: First Affiliated Hospital of Harbin Medical University class: OTHER briefSummary: 1. Explore the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cardiovascular risk factors; 2. Discuss the correlation between different risk factors (mainly hypertension, diabetes, smoking, hyperlipidemia, hyperhomocysteinemia, etc.) and the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cerebrovascular diseases and immune-inflammatory related diseases of the nervous system; 3. Explore the correlation between different immune inflammatory factors (IL1, IL6, IL10, INFγ, TNFα) and the expression level of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients; 4. Track and explore the dynamic changes of immune checkpoint VISTA in peripheral blood and cerebrospinal fluid of patients with cardiovascular risk factors in 3 months, 1 year, 3 years, and 5 years. conditions: Cerebrovascular Disease Small Vessel studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 400 type: ESTIMATED name: Neuropsychological testing measure: Patient characteristics measure: VISTA expression in PBMCs in the VCI and control groups sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: First Affiliated Hospital of Harbin Medical University status: RECRUITING city: Harbin state: Heilongjiang zip: 150010 country: China name: LiJun Chi role: CONTACT phone: 13895783757 email: clj3757@163.com lat: 45.75 lon: 126.65 hasResults: False
nctId: NCT06342648 id: Cutaneous water in renal colic briefTitle: Intracutaneous Sterile Water and Diclofenac Sodium Injections in Renal Colic overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-10-30 date: 2024-12-30 date: 2024-04-02 date: 2024-04-02 name: Suez Canal University class: OTHER briefSummary: Renal colic is a serious and excruciatingly painful condition that frequently presents itself in the emergency department. In this trial, patients with renal colic who have received intramuscular diclofenac sodium injection or intracutaneous sterile water injection will have their Visual Analogue Scale (VAS) measured and compared. conditions: Renal Colic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 570 type: ESTIMATED name: Sterile Water Injection name: Diclofenac Sodium injection measure: Visual Analogue Scale (VAS) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06342635 id: HYD/DENMARK-001/2023 briefTitle: Hydra Single-centre Experience - Copenhagen, Denmark overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-09-30 date: 2026-10-31 date: 2024-04-02 date: 2024-04-02 name: Sahajanand Medical Technologies Limited class: INDUSTRY name: Qmed Consulting A/S briefSummary: The present study aims to evaluate the efficacy and safety of TAVI using the Hydra transcatheter aortic valve (THV) series, in patients with severe aortic stenosis up to 1-year after the procedure. Additionally, the study will assess the role of geometry in the development of new conduction abnormalities based on the analysis of post-operative CT scan at 1-month in patients who had undergone transcatheter aortic valve replacement with a self-expanding Hydra THV series. conditions: Aortic Valve Stenosis studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Hydra Transcatheter Aortic Valve (THV) Series measure: Primary safety endpoint measure: Primary performance endpoint measure: Technical success measure: Cardiovascular mortality measure: All-cause mortality measure: All stroke measure: Disabling stroke measure: Myocardial infarction measure: Major vascular complication measure: Acute kidney injury measure: New permanent pacemaker implantation due to procedure related conduction abnormalities measure: New-onset atrial fibrillation measure: Coronary artery obstruction requiring intervention measure: Re-hospitalization for procedure- or valve-related causes measure: Mean aortic valve gradient measure: Effective Orifice Area (EOA) measure: Paravalvular leak measure: New York Heart Association (NYHA) functional class measure: Quality-of-life evaluation measure: Bioprosthetic Valve Failure (BVF) measure: Bioprosthetic valve dysfunction (BVD) measure: Stroke or peripheral embolism measure: VARC-3 Type 3-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents used specifically for valve-related concerns measure: Rates of Hypoattenuated Leaflet Thickening (HALT) measure: Rates of Reduced leaflet motion (RLM) measure: Commissural alignment sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Copenhagen University Hospital, Rigshospitalet city: Copenhagen country: Denmark name: Dr. Ole De Backer role: CONTACT name: Dr. Ole De Backer, Copenhagen University Hospital, Rigshospitalet role: PRINCIPAL_INVESTIGATOR lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06342622 id: Weiguo Dong briefTitle: Young-onset Colorectal Cancer Screening Based on Artificial Intelligence overallStatus: COMPLETED date: 2023-12-01 date: 2024-01-10 date: 2024-01-25 date: 2024-04-02 date: 2024-04-02 name: Renmin Hospital of Wuhan University class: OTHER briefSummary: In this study, we aimed to develop, internally and temporally validate the machine learning models to help screen YOCRC bansed on the retrospective extracted Electronic Medical Records (EMR) data. conditions: Colorectal Cancer studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 11000 type: ACTUAL name: Using routine clinical data and machine learning models. measure: The performance of machine learning screening models sex: ALL minimumAge: 18 Years maximumAge: 49 Years stdAges: ADULT facility: Renmin Hospital of Wuhan University city: Wuhan state: Hubei zip: 430060 country: China lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06342609 id: 32857-01-EKSTROM briefTitle: Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease acronym: EKSTROM overallStatus: ACTIVE_NOT_RECRUITING date: 2023-03-15 date: 2024-09-07 date: 2024-09-07 date: 2024-04-02 date: 2024-04-02 name: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center class: OTHER briefSummary: This is a randomized double-blind, placebo-controlled, investigator-initiated trial that compares Colchicine 0.5mg/day with placebo, among patients with stable CAD. Subjects will be educated to maintain medication compliance with other prescribed medications. conditions: Coronary Artery Disease studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Double blind Placebo controlled primaryPurpose: HEALTH_SERVICES_RESEARCH masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 84 type: ACTUAL name: Colchicine 0.5 MG measure: Rate of change in low attenuation plaque volume as measured by multidetector computed tomography (MDCT) angiography measure: Effect of Colchicine on markers of inflammation using laboratory tests measure: Effects of Colchicine on Pericoronary Adipose Tissue (PCAT) volume using CTA measure: Effects of Colchicine on Epicardial Adipose Tissue (EAT) volume using CTA measure: Effect of Colchicine on the markers of Endothelial Function using Flow-mediated dilation (FMD) sex: ALL minimumAge: 30 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center city: Torrance state: California zip: 90502 country: United States lat: 33.83585 lon: -118.34063 hasResults: False